GCC19CART, a novel CAR T-cell therapy, demonstrated clinical antitumor activity in patients with refractory metastatic colorectal cancer (mCRC) in an ongoing phase 1 trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.